Venous thromboembolism and COVID-19: guidance on prevalence, incidence and treatment

Added September 14, 2020

Citation: Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. Chest. 2020 Sep;158(3):1143-63.

What is this? Some patients with COVID-19 will become critically ill and might develop venous thromboembolism (VTE).

In this rapid systematic review, which was done for a clinical guideline, the authors searched for studies on the prevalence, incidence or treatment of VTE in COVID-19 patients. They also convened an expert panel to produce recommendations for the guideline.

What was found: At the time of this review, the authors concluded that there was very little evidence about VTE in the COVID-19 population. The expert panel used consensus and existing evidence-based guidelines to develop summary recommendations for the prevention, diagnosis and treatment of VTE in COVID-19 patients.

 

Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.

Share